Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2007 4
2008 6
2009 11
2010 19
2011 28
2012 32
2013 36
2014 37
2015 36
2016 25
2017 23
2018 26
2019 21
2020 26
2021 31
2022 20
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

336 results
Results by year
Filters applied: . Clear all
Page 1
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Yatham LN, et al. Bipolar Disord. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609. Epub 2018 Mar 14. Bipolar Disord. 2018. PMID: 29536616 Free PMC article.
Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence-based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazin …
Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making ev …
New Antipsychotic Medications in the Last Decade.
Pahwa M, Sleem A, Elsayed OH, Good ME, El-Mallakh RS. Pahwa M, et al. Curr Psychiatry Rep. 2021 Nov 29;23(12):87. doi: 10.1007/s11920-021-01298-w. Curr Psychiatry Rep. 2021. PMID: 34843030 Review.
RECENT FINDINGS: We identified 11 significant developments: the introduction of new antipsychotics cariprazine, brexpiprazole, lumateperone, and pimavanserin; introduction of new delivery methods: subcutaneous long-acting risperidone, aripiprazole lauroxil, transdermal asenapi …
RECENT FINDINGS: We identified 11 significant developments: the introduction of new antipsychotics cariprazine, brexpiprazole, lumateperone, …
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Leucht S, et al. Lancet. 2013 Sep 14;382(9896):951-62. doi: 10.1016/S0140-6736(13)60733-3. Epub 2013 Jun 27. Lancet. 2013. PMID: 23810019 Review.
METHODS: We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia …
METHODS: We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised cont …
How to treat mania.
Pacchiarotti I, Anmella G, Colomer L, Vieta E. Pacchiarotti I, et al. Acta Psychiatr Scand. 2020 Sep;142(3):173-192. doi: 10.1111/acps.13209. Epub 2020 Aug 3. Acta Psychiatr Scand. 2020. PMID: 33460070 Review.
Findings have been synthesized and incorporated with clinical experience into a model to support different treatment choices. RESULTS: To date, there is solid evidence supporting the use of several medications, such as lithium, divalproex, and carbamazepine, and antipsycho …
Findings have been synthesized and incorporated with clinical experience into a model to support different treatment choices. RESULTS: To da …
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations.
Yatham LN, Chakrabarty T, Bond DJ, Schaffer A, Beaulieu S, Parikh SV, McIntyre RS, Milev RV, Alda M, Vazquez G, Ravindran AV, Frey BN, Sharma V, Goldstein BI, Rej S, O'Donovan C, Tourjman V, Kozicky JM, Kauer-Sant'Anna M, Malhi G, Suppes T, Vieta E, Kapczinski F, Kanba S, Lam RW, Kennedy SH, Calabrese J, Berk M, Post R. Yatham LN, et al. Bipolar Disord. 2021 Dec;23(8):767-788. doi: 10.1111/bdi.13135. Epub 2021 Nov 1. Bipolar Disord. 2021. PMID: 34599629 Review.
For mania + mixed features second-line treatment options include asenapine, cariprazine, divalproex, and aripiprazole. In depression + mixed features, cariprazine and lurasidone are recommended as second-line options. For DSM-IV defined mixed episodes, with a longer histor …
For mania + mixed features second-line treatment options include asenapine, cariprazine, divalproex, and aripiprazole. In depression …
New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression.
Orzelska-Górka J, Mikulska J, Wiszniewska A, Biała G. Orzelska-Górka J, et al. Int J Mol Sci. 2022 Sep 13;23(18):10624. doi: 10.3390/ijms231810624. Int J Mol Sci. 2022. PMID: 36142523 Free PMC article. Review.
The purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripiprazole, cariprazine, lurasidone, asenapine, brexpiprazole, lumateperone, pimavanserin) in treatment of schizophrenia and depression. …
The purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripip …
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Leucht S, et al. Am J Psychiatry. 2020 Apr 1;177(4):342-353. doi: 10.1176/appi.ajp.2019.19010034. Epub 2019 Dec 16. Am J Psychiatry. 2020. PMID: 31838873
The 95% effective doses and the doses equivalent to 1 mg of oral risperidone, respectively, were as follows: amisulpride for patients with positive symptoms, 537 mg/day and 85.8 mg; aripiprazole, 11.5 mg/day and 1.8 mg; aripiprazole LAI (lauroxil), 463 mg every 4 weeks and 264 mg …
The 95% effective doses and the doses equivalent to 1 mg of oral risperidone, respectively, were as follows: amisulpride for patients with p …
Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.
Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, Altamura AC. Mauri MC, et al. Clin Pharmacokinet. 2018 Dec;57(12):1493-1528. doi: 10.1007/s40262-018-0664-3. Clin Pharmacokinet. 2018. PMID: 29915922 Review.
Therapeutic drug monitoring studies have generally concentrated on controlling compliance and avoiding side effects by maintaining long-term exposure to minimally effective blood concentrations. The rationale for using therapeutic drug monitoring in relation to seco …
Therapeutic drug monitoring studies have generally concentrated on controlling compliance and avoiding side effects by maintaining lo …
A History of the Pharmacological Treatment of Bipolar Disorder.
López-Muñoz F, Shen WW, D'Ocon P, Romero A, Álamo C. López-Muñoz F, et al. Int J Mol Sci. 2018 Jul 23;19(7):2143. doi: 10.3390/ijms19072143. Int J Mol Sci. 2018. PMID: 30041458 Free PMC article. Review.
In this paper, the authors review the history of the pharmacological treatment of bipolar disorder, from the first nonspecific sedative agents introduced in the 19th and early 20th century, such as solanaceae alkaloids, bromides and barbiturates, to John Cade's experiments …
In this paper, the authors review the history of the pharmacological treatment of bipolar disorder, from the first nonspecific sedative agen …
336 results